Recombinant Anti-CD3 x Anti-CXCR5 Bispecific Antibody (scFv-Fc-scFv) is designed to be expressed as one chain, then assembled to a homodimer of bivalent scFv fragments and the Fc region of IgG. The anti-CD3 scFv is fused to the N-terminus of Fc via a hinge region while another anti-CXCR5 scFv is linked to the C-terminus of Fc. This scFv-Fc-scFv format has 2+2 antigen-binding valency by employing different scFv fragments. This BsAb can retarget T cells to tumor cells. It is designed for the research of Non-Hodgkin's lymphoma (NHL) therapy.